Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis

Cutaneous Leishmaniasis Clinical Trial

Official title:

A Phase I/II Randomized Comparison of Localized Heat Therapy Versus Sodium Stibogluconate (Pentostam) for the Treatment of Old World Cutaneous Leishmaniasis (HSRRB Log No. A-12364)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00884377
• Other study ID #: A-12364
• Status: Completed
• Phase: Phase 2
• Start date: February 2004
• Est. completion date: March 2009

Study information

• Verified date: December 2019
• Source: U.S. Army Medical Research and Development Command
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study serves to compare the effectiveness of treating cutaneous leishmaniasis with either intravenous sodium stibogluconate or direct heat therapy using the ThermoMed-TM device.

Description:

A total of 56 Department of Defense health care beneficiaries, 18 years of age or older and diagnosed with cutaneous leishmaniasis, were planned to be treated with either intravenous sodium stibogluconate (Pentostam-TM) or the ThermoMed-TM device of Thermosurgery Technologies, Inc. at the Walter Reed Army Medical Center. Pentostam is the standard of care for this disease, but the i.v. administration and the many known side effects prompt the search for an improved method of treating this disease, especially for milder cases. This study compares the safety and efficacy of these two treatment approached.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: March 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Department of Defense (DOD) Healthcare beneficiary

• Parasitologic diagnosis of cutaneous Leishmania infection

(Inclusion criteria for randomization includes that must be Leishmania major species)

• Willing to locate to WRAMC area during treatment and perform subsequent follow-up visits if needed

(If not active duty on orders, then the participant will bear the cost of food and lodging during the initial 10-day outpatient treatment period at Walter Reed Army Medical Center)

• Able to provide informed consent

• All participants (both male and female) must agree to take precautions not to become pregnant or father a child for at least 2 months after receiving sodium stibogluconate

Exclusion Criteria:

• Unable to provide informed consent

• Pregnancy (females of child bearing potential must have negative urine human chorionic gonadotropic hormone [HCG] within 48 hours of the start of infusion period)

• History of hypersensitivity to pentavalent antimonials

• Serious medical illness:

1. QTc interval >/= 0.5 sec

2. severe cardiac disease

3. history of current pancreatitis

4. liver failure or active hepatitis with transaminases >3X normal

5. renal failure or creatinine >2.5

6. thrombocytopenia (platelets <75,000)

7. white blood cell count <2000

8. hematocrit <25

9. absence of palpable extremity pulses in the limb requiring treatment

• History of serious allergic reaction to local anesthetics

• Location of lesion not amenable to local therapy (such as close to eye, mucous membranes, face, cartilage)

• Presence of pacemaker and/or other implanted metallic devices

• Breast feeding

• Men unwilling to avoid fathering a child during and/or in the two months following receiving the treatment

• Women unwilling to avoid pregnancy for at least two months after receiving the treatment

• More than 20 lesions, or multiple lesions which in the opinion of the investigator would not be well treated with heat therapy

Related Conditions & MeSH terms

• Cutaneous Leishmaniasis
• Leishmaniasis
• Leishmaniasis, Cutaneous

Intervention

Drug:
• Sodium stibogluconate (Pentostam)
intravenous 20 mg/kg/day for 10 days

Device:
• ThermoMed
ThermoMed heat treatment device, one treatment

Locations

Country	Name	City	State
United States	Walter Reed Army Medical Center	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
U.S. Army Medical Research and Development Command	Walter Reed Army Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Equivalence of Efficacy Assessed by the Number of Participants With Clinical Cure	Assess whether local heat therapy using the ThermoMed device was equivalent (clinical cure) in efficacy to 10 days of parenteral sodium stibogluconate. Clinical cure is defined as complete epithelialization of lesion. post-treatment, photographs of treated lesions were assessed for efficacy outcome by a consensus decision of leishmaniasis experts blinded as to each subject's study group. On the basis of these photo assessments, "clinical response" was assessed by lesion and by subject. In addition, an "overall response" was assigned ("healed" or "not healed") based on a combination of experts' photo assessments and subject interviews. Efficacy outcomes for the 2 study groups were compared using the Fishers exact test.	Assessment of cure is made at 2 months after treatment
Secondary	Equivalence of Efficacy (Clinical Cure) of TheroMed Treatment vs Sodium Stibogluconate Assessed by the Number of Subjects With Clinical Cure	Determine the equivalence of efficacy (clinical cure) of ThermoMed treatment vs sodium stibogluconate in clinical response of all skin lesions at 12 months. Clinical cure is defined as complete epithelialization of lesion. Post-treatment, photographs of treated lesions were assessed for efficacy outcome by a consensus decision of leishmaniasis experts blinded as to each subject's study group. On the basis of these photo assessments, "clinical response" was assessed by lesion and by subject. In addition, an "overall response" was assigned ("healed" or "not healed") based on a combination of experts' photo assessments and subject interviews. Efficacy outcomes for the 2 study groups were compared using the Fishers exact test.	12 months
Secondary	Number of Participants With Solicited Adverse Events	To compare the toxicity profiles of ThermoMed treatment versus parenteral sodium stibogluconate therapy thru specific solicited adverse events	Days 3, 7 and 10
Secondary	Immune Response, Based on T-Cell Population Before Treatment, and Day 10 Following Treatments	Evaluate the immune response (T-Cell population) to Leishmania before treatment, and at 10 days, in recipients of localized heat therapy vs systemic sodium stibogluconate. Days 1 and 10 are presented in columns.	day 1 and day 10
Secondary	Immune Response, Based on Percent of T-Cell Population Before Treatment, and Day 10 Following Treatments	Evaluate the immune response (T-Cell population) to Leishmania before treatment, and at 10 days, in recipients of localized heat therapy vs systemic sodium stibogluconate. Days 1 and 10 are presented in columns.	day 1 and day 10
Secondary	Feasibility of a L. Major Species Specific Polymerase Chain Reaction as a Rapid Diagnostic Device in the Context of a Treatment Trial	Evaluate the feasibility of using species-specific PCR as a rapid diagnostic assay for L. major infection. The comparator modalities were: histopathology (identification of amastigotes); speciation determined through culture and isoenzyme analysis; and genus and species-specific PCR. Species PCR testing was performed at baseline to allow for the identification of L. major as each subject's infecting parasite. If an L. major infection could not be confirmed in a subject's lesion(s), then that subject could not be treated under this protocol.	at baseline before treatment